Taken together, our data and previous reports raise the possibility that central glutamine deficiency may upregulate slc1a5 and Slc7a5 gene expression, activate the mTOR pathway, and contribute to astrogliosis and epilepsy, some of the key features of experimental SSADHD. This evidence concerns the gene SLC7A5 and succinic semialdehyde dehydrogenase deficiency.